QL-007
- Generic Name
- QL-007
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Entecavir or Tenofovir in Patients With Chronic Hepatitis b Who Have Received Nucleoside (Acid) Therapy
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-08
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 60
- Registration Number
- NCT04157257
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of jilin university, Changchun, Jilin, China
An Study to Evaluate Safety and Efficacy of QL-007 Tablets in Combination With Tenofovir in Naive Patients With Chronic Hepatitis b
- First Posted Date
- 2019-11-08
- Last Posted Date
- 2019-11-12
- Lead Sponsor
- Qilu Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT04157699
- Locations
- 🇨🇳
Southern Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The first hospital of Jilin university, Changchun, Jilin, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath